Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Inclusion Criteria: * Healthy males and females in good general health, 19-49 years of age * Subjects must provide written consent * Willing to participate through study completion * Willing to undergo nasal washes and swabs and provide urine and blood samples per protocol for safety and immunogenicity analysis * Female of child-bearing age must have a negative urine pregnancy test and be stable on a reliable means of contraception. * Meet screening criteria for hematology, chemistry and urinalysis Exclusion Criteria: * Pregnant (or possibly pregnant) and lactating women * Any flu/cold symptoms and/or fever greater than 101 degrees in 3 days prior to study enrollment * Any intranasal steroid medication administered in the 10 days prior to study enrollment * History of chronic rhinitis or presence of pre-existing nasal septal defects, nasal polyps or other gross abnormalities * Any previous nasal cautery or significant surgery for nasal septal defects * Any regular past or current use of intranasal illicit drugs or history of intravenous illicit drug use * Asthma that is greater than mild in severity * Diagnosed active Hepatitis B or C * HIV positive at screening * Known or suspected malignancy, leukemia, or lymphoma * Immunosuppressed, altered or compromised immune status as a consequence of disease or treatment with systemic corticosteroids * Receipt of an influenza vaccine within the past 6 months * Receipt of any vaccine in the past 30 days * Receipt of any investigational drug in the past 30 days * Known Diabetes mellitus * History of anaphylaxis or angioedema * Hypertension that is not well controlled * Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator would serve to interfere or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participants's ability to give informed consent